Dose response effect of cyclical medroxyprogesterone on blood pressure in postmenopausal women

Journal of Human Hypertension

Volumn 15, Issue 5, 2001, Pages 313-321

  Harvey, Paula J ^a,b   Molloy, D ^a   Upton, J ^a   Wing, L M ^a  

^a FLINDERS UNIVERSITY   (Australia)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Ambulatory blood pressure; Arterial pulse waveform; Blood pressure; Menopause; Oestrogen; Progestogen

Indexed keywords

CONJUGATED ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; PLACEBO;

ADULT; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HORMONE SUBSTITUTION; HUMAN; MEAN ARTERIAL PRESSURE; POSTMENOPAUSE; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL;

AGED; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CHI-SQUARE DISTRIBUTION; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEART RATE; HEMODYNAMIC PROCESSES; HUMANS; MEDROXYPROGESTERONE; MIDDLE AGED; POSTMENOPAUSE; PROBABILITY; PROGESTINS; REFERENCE VALUES;

EID: 0035026817     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001180     Document Type: Article

References (65)

1. Harvey PJ, Wing LM, Savage J, Molloy D. The effects of different types and different doses of oestrogen replacement therapy on clinic and ambulatory blood pressure and the renin-angiotensin system in normotensive postmenopausal women. J Hypertens 1999; 17: 405-411.
2. Myrup B, Jensen GF, McNair P. Cardiovascular risk factors during estrogen-norethindrone and cholecalciferol treatment. Arch Intern Med 1992; 152: 2265-2268.
3. Lieberman EH et al. Estrogen improves endothelium-dependent, flow-mediated vasodilatation in postmenopausal women. Ann Intern Med 1994; 121: 936-941.
4. Brons M, Jacobsen JG, Kristoffersen K. Changes in plasma renin concentration, activity and substrate after twenty-eight days' treatment with micronized estrogen, ethinylestradiol and norethisterone-acetate in postmenopausal women. Acta Med Scand 1981; 209 (suppl 646): 94-97.
5. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995; 273: 199-208.
6. Saleh AA et al. Thrombosis and hormone replacement therapy in postmenopausal women. Am J Obstet Gynecol 1993; 169: 1554-1557.
7. Prough S, Aksel S, Wiebe R, Shepherd J. Continuous estrogen/progestin therapy in menopause. Am J Obstet Gynecol 1987; 157: 1449-1453.
8. Hargrove J, Maxson W, Wentz A, Burnett L. Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone. Obstet Gynecol 1989; 73: 606-612.
9. Gow S, MacGillivray I. Metabolic, hormonal, and vascular changes after synthetic oestrogen therapy in oophorectomized women. Br Med J 1971; 2: 73-77.
10. Medical Research Council's General Practice Framework. Randomized comparison of oestrogen versus oestrogen plus progestogen hormone replacement therapy in women with hysterectomy. Br Med J 1996; 312: 473-478.
11. Akkad AA, Halligan AWF, Abrams K, Al-Azzawi F. Differing responses in blood pressure over 24 hours in normotensive women receiving oral or transdermal estrogen replacement therapy. Obstet Gynecol 1997; 89: 97-103.
12. Pripp U et al. A randomized trial on effects of hormone therapy on ambulatory blood pressure and lipoprotein levels in women with coronary artery disease. J Hypertens 1999; 17: 1379-1386.
13. Mercuro G et al. Does the menopause play a role as a risk factor for essential hypertension? Circulation 1998; 78: 861-864.
14. Alfie J et al. Hemodynamic effects of transdermal estradiol alone and combined with norethisterone acetate. Maturitas 1997; 27: 163-169.
15. Sudhir K, Esler MD, Jennings GL, Komesaroff PA. Estrogen supplementation decreases norepinephrine-induced vasoconstriction and total body norepinephrine spillover in perimenopausal women. Hypertension 1997; 30: 1538-1543.
16. Lind T et al. A prospective, controlled trial of six forms of hormone replacement therapy given to postmenopausal women. Br J Obstet Gynaecol 1979; 86 (Suppl 3): 1-29.
17. Luotola H. Blood pressure and hemodynamics in postmenopausal women during estradiol-17-beta substitution. Ann Clin Res 1983; 15(Suppl 38): 1-121.
18. Hassager C et al. The long-term effect of oral and percutaneous estradiol on plasma renin substrate and blood pressure. Circulation 1987; 76: 753-758.
19. Hassager C, Christiansen C. Blood pressure during oestrogen/progestogen substitution therapy in healthy post-menopausal women. Maturitas 1988; 9: 315-323.
20. Kable WT, Gallagher JC, Nachtigall L, Goldbar D. Lipid changes after hormone replacement therapy for menopause. J Reprod Med 1990; 35: 512-518.
21. Wren B, Routledge AD. The effect of type and dose of oestrogen on the blood pressure of post-menopausal women. Maturitas 1983; 5: 135-142.
22. Staland B. Continuous treatment with natural oestrogens and progestogens. A method to avoid ondometrial stimulation. Maturitas 1991; 3: 145-156.
23. MacLennan AH et al. Oestrogen and cyclical progestogen in postmenopausal hormone replacement therapy. Med J Aust 1992; 157: 167-170.
24. Seely EW, Walsh BW, Gerhard MD, Williams GH. Estradiol with or without progesterone and ambulatory blood pressure in postmenopausal women. Hypertension 1999; 33: 1190-1194.
25. van Ittersum FJ et al. Ambulatory-not office-blood pressures decline during hormone replacement therapy in healthy postmenopausal women. Am J Hypertens 1998; 11: 1147-1152.
26. Manwaring P, Morfis L, Diamond T, Howes LG. Effects of hormone replacement therapy on ambulatory blood pressure and vascular responses in normotensive women. Blood Pressure 2000; 9: 22-27.
27. Manhem K, Ahlm H, Milsom I, Svensson A. Transdermal oestrogen reduces daytime blood pressure in hypertensive women. J Hum Hypertens 1998; 12: 323-327.
28. Mercuro G et al. Estradiol-17beta reduces blood pressure and restores the normal amplitude of the circadian blood pressure rhythm in postmenopausal women. Am J Hypertens 1998; 11: 909-913.
29. Szekacs B et al. Hormone replacement therapy reduces mean 24-hour blood pressure and its variability in postmenopausal women with treated hypertension. Menopause 2000; 7: 31-35.
30. Crane MG, Harris JJ, Winsor W. Hypertension, oral contraceptive agents, and conjugated estrogens. Ann Intern Med 1971; 74: 13-21.
31. Spellacy WN, Birk SA. The effect of intrauterine devices, oral contraceptives, estrogens, and progestogens on blood pressure. Am J Obstet Gynecol 1972; 112: 912-919.
32. Notelovitz M. Effect of natural oestrogens on blood pressure and weight in postmenopausal women. S African Med J 1975; 49: 2251-2254.
33. Weinstein L, Bewtra C, Gallagher J. Evaluation of a continuous combined low-dose regimen of oestrogen-progestin for treatment of the menopausal patient. Am J Obstet Gynecol 1990; 162: 1534-1542.
34. Plunkett ER, Wolfe BM. Prolonged effects of a novel, low dosage continuous progestin-cyclic estrogen replacement program in postmenopausal women. Am J Obstet Gynecol 1992; 166: 117-121.
35. Pfeffer RI. Estrogen use, hypertension and stroke in postmenopausal women. J Chron Dis 1978; 31: 389-398.
36. Hall WD, Douglas MB, Blumenstein BA, Hatcher RA. Blood pressure and oral progestational agents. A prospective study of 119 black women. Am J Obstet Gynecol 1980; 136: 344-348.
37. Wilson ESB, Cruickshank J, McMaster M, Weir RJ. A prospective controlled study of the effect on blood pressure of contraceptive preparations containing different types and dosages of progestogen. Br J Obstet Gynaecol 1984; 91: 1254-1260.
38. Rylance PB et al. Natural progesterone and antihypertensive action. Br Med J 1985; 290: 13-14.
39. Wren B. The effect of oestrogen on the female cardiovascular system. Med J Aust 1992; 157: 204-208.
40. Lobo RA, Stanczyk FZ. New knowledge in the physiology of hormonal contraceptives. Am J Obstet Gynecol 1994; 170: 1499-1507.
41. Williams JK, Adams MR. Estrogens, progestins and coronary artery reactivity. Nat Med 1997; 3: 273-274.
42. Rosselli M et al. Circulating nitric oxide (nitrite/ nitrate) levels in postmenopausal women substituted with 17β-estradiol and norethisterone acetate. A two-year follow-up study. Hypertension 1995; 25: 848-853.
43. Lobo RA. The role of progestins in hormone replacement therapy. Am J Obstet Gynecol 1992; 166: 1997-2004.
44. Williams JK, Honoré EK, Washburn SA, Clarkson TB. Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. J Am Coll Cardiol 1994; 24: 1757-1761.
45. Anon. Advice on contraception around the menopause. Drug Ther Bull 1992; 30: 95-96.
46. Granberg S et al. Endometrial thickness as measured by endovaginal ultrasonography for identifying endometrial abnormality. Am J Obstet Gynecol 1991; 164: 47-52.
47. MacLennan AH, Taylor AW, Wilson DH. Changes in the use of hormone replacement therapy in South Australia. Med J Aust 1995; 162: 420-422.
48. Posey JA, Geddes LA, Williams H, Moore AG. The meaning of the point of maximum oscillations in cuff pressure in the indirect measurement of blood pressure. Part 1. Cardiovasc Res Cent Bull 1969; 8: 15-25.
49. Prisant LM, Alpert BS, Robbins CB. American National Standard for non-automated sphygmomanometers: summary report. Am J Hypertens 1995; 8: 210-213.
50. Prasad N, MacFadyen RJ, Ogston SA, MacDonald TM. Elevated blood pressure during the first two hours of ambulatory blood pressure monitoring: a study comparing consecutive twenty-four-hour monitoring periods. J Hypertens 1995; 13: 291-295.
51. Kelly RP et al. Non-invasive registration of the arterial pulse waveform using high-fidelity applanation tonometry. J Vas Med Biol 1989; 1: 142-149.
52. Kelly RP, Hayward CS, Avolio AP, O'Rouke MF. Non-invasive determination of age-related changes in the human arterial pulse. Circulation 1989; 80: 1652-1659.
53. Bonnin JM, Cain MD, Jose JS. Hypertension due to a renin secreting tumour localised by segmental renal vein sampling. Aust N Z J Med 1977; 7: 630-635.
54. Ogihara T et al. A non-chromatographic non-extraction radioimmunoassay for serum aldosterone. J Clin Endocrinol Metab 1977; 45: 726-731.
55. BMDP statistical software manual volume 2: to accompany the 7.0 software release (1992). Dixon WJ (editor): Los Angeles: University of California Press, 1992, pp 1435-1436.
56. Ludbrook J, On making multiple comparisons in clinical and experimental pharmacology and physiology. Clin Exp Pharmacol Physiol 1991; 18: 379-392.
57. Stata statistical software manual volume 4: to accompany the 6.0 release (1999). Stata Press, University Drive East, College Station, Texas, USA, 1999, p 420.
58. Armitage P, Berry G. Distribution free methods. In: Armitage P, Berry G (eds). Statistical Methods in Medical Research. Third edition. Blackwell Scientific Publications: Oxford, 1994, pp 448-468.
59. Armitage P, Berry G. The planning of statistical investigations. In: Armitage P, Berry G (eds). Statistical Methods in Medical Research Third edition. Oxford: Blackwell Scientific Publications, 1994, pp 175-206.
60. Goodman HM. Progestins. In: Goodman HM, Munson PL (eds). Principles of Pharmacology. Basic concepts and clinical applications. Chapman and Hall; 1995, pp 827-836.
61. Berger DS, Li JK. Concurrent compliance reduction and increased peripheral resistance in the manifestation of isolated systolic hypertension. Am J Cardiol 1990; 65: 67-71.
62. O'Rourke M, Kelly RP. Wave reflection in the systemic circulation and its implications in ventricular function. J Hypertens 1993; 11: 327-337.
63. Wise AJ, Gross MA, Schalch DS. Quantitative relationships of the pituitary-gonadal axis in postmenopausal women. J Lab Clin Med 1973; 81: 28-36.
64. Kuhl H. Comparative pharmacology of newer progestogens. Drugs 1999; 51: 188-215.
65. Stumpf PG. Pharmacokinetics of estrogon. Obstet Gynecol 1990; 75 (Suppl): 9s-14s.